H.C. Wainwright initiated coverage on PepGen with a new price target
$PEPG
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage of PepGen with a rating of Buy and set a new price target of $26.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/16/2024 | $3.00 | Neutral → Underperform | BofA Securities |
| 7/31/2024 | $12.00 | Buy → Neutral | BofA Securities |
| 12/21/2022 | $26.00 | Buy | H.C. Wainwright |
BofA Securities downgraded PepGen from Neutral to Underperform and set a new price target of $3.00
BofA Securities downgraded PepGen from Buy to Neutral and set a new price target of $12.00
H.C. Wainwright initiated coverage of PepGen with a rating of Buy and set a new price target of $26.00
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) for patients amenable to an exon-51 skipping approach. CONNECT1-EDO51: Phase 2, open-label, multiple ascending dose (MAD) clinical trial being conducted in Canada. CONNECT1 has enrolled two cohorts of boys and young men living with DMD amenable to exon 51 skipping and its endpoints include safety and tolerability, dystrophin production, exon skipping
-Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application to initiate the CONNECT2-EDO51 clinical trial in patients with Duchenne muscular dystrophy (DMD). The FDA indicated they will provide an official clinical hold letter to the Company within 30 days. CO
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen's 2024 Inducement Plan as a material inducement to employment to its newly appointed Senior Vice President, Clinical Development, Steve Han, MD, PhD, MMSc. On November 20, 2024, Dr. Han received a non-qualified stock option grant to purchase 95,000 shares of PepGen's common stock, par value $0.0001 per share, with an exercise price of $4.40 per share, the closing price of PepGen's common stock as reported by The N
SC 13G/A - PepGen Inc. (0001835597) (Subject)
SC 13G - PepGen Inc. (0001835597) (Subject)
SC 13G/A - PepGen Inc. (0001835597) (Subject)
4 - PepGen Inc. (0001835597) (Issuer)
3 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4/A - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization. "We are very pleased that Paul is joining PepGen at such an important time for the Company," said James McArthur, Ph.D., President and CEO of PepGen. "Throughout his career, Paul has served in leadership roles across both l
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointments of Afsaneh Mohebbi, Ph.D., as Senior Vice President, Portfolio and Program Management and Dave Borah, CFA, as Senior Vice President, Investor Relations and Corporate Communications, effective immediately. "We are thrilled to welcome Afsaneh and Dave to PepGen. The addition of these two senior team members will enhance our expertise in critical areas of the organization, and we eagerly anticipate thei
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointment of Mary Beth DeLena as General Counsel and Secretary. Ms. DeLena joins PepGen with over 20 years of experience advising global life science companies in a broad range of strategic, transactional, and corporate matters with extensive experience in business development, finance, securities, corporate governance, employment and commercial law. Prior to PepGen, Ma
SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)
SCHEDULE 13G - PepGen Inc. (0001835597) (Subject)
SCHEDULE 13G - PepGen Inc. (0001835597) (Subject)
– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, will report its fourth quarter and full year 2022 financial results and provide a corporate update on Thursday, March 23, 2023. PepGen's management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30pm ET. The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen's website. A replay of the event will be archived
- PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 skipping approaches - - PGN-EDO51 was generally well-tolerated - - PepGen plans to initiate a Phase 2a multiple ascending dose (MAD) clinical trial in Duchenne muscular dystrophy (DMD) patients in 1H 2023 - - Data supports the potential of PepGen's Enhanced Delivery Oligonucleotide (EDO) platform in neuromuscular diseases - - Company to host conference call today at 8:00 a.m. ET to discuss these results - BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-sta